Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > $3.50

<< Previous

Bullboard Posts

Next >>

Comment by SABBOBCATon Nov 04, 2021 1:24pm

70 Views

Post# 34087588

RE:RE:RE:$3.50

Isnt Cantor the one doing the ATM? If so they are likely research restricted on it and wont publish anything until it is complete.

SPCEO1 wrote: I suppose those that want to be pre-postioned prior to the oncology results are already mostly there with a few late traders still likely to come in, especially if Paul gives some indications about the exact timing of when those results might become available next week at CS First Boston. Given what we do know, taking the short side of this news event would seem to be quite brave. I am not sure who would be selling right now or on what basis other than there is always uncertainty, so you would think there would be some upside bias as buyers would outnumber sellers on the margin. But potential buyers are not really aware of the situation with TH-1902 as there is no broker telling them about it and no other way for TH to adequately distribute information about TH-1902 (at least that they seem interested in using!). Cantor will likely change that at some point. My best guess is that Cantor will come out with an optimistic report prior to the release of the phase 1a results and then follow up with a more optimistic report after those results are released, assuming the results are good, where they raise the share price target, generate some excitement about the phase 1b results, start putting some numbers around the possible revenues, etc. And then they do the ATM offering in order to raise the money for the NASH trial's first 400 patients. Then both the NASH trial and the phase 1b get started early in 2022. We will have a long wait for the interim readout on NASH but the phase 1b could give us some results as early as the Spring depending on when it actually starts and how many doses it takes before they start seeing a response.

jfm1330 wrote: The volume is very low. It is wait and see on both sides. We all wait for the same thing: oncology results.

SPCEO1 wrote: The price of THTX is stuck at $3.50 and has been for several weeks now. This lack of movement, despite news of insider buying and the appointment of Dr. Rothenberg as well as interst in TH's SORT1+ platform and a huge bull run in the market is not a normal situation and one wonders what forces are at work that is leading to the stock flatlining at this level.

I don't have any great explanations, unfortunately.

Could there be both a buyer and a seller of some size who both think $3.50 is the price they want to transact at and their respective algos are just working with each other over a number of weeks. Could Cantor be acquiring a position for later disposition at a profit when they put out a report complimentary of TH in preparation for the ATM offering?

Of course, we cannot really know what is going on, but it sure is odd.